Safety, Phamacokinetics (PK), Pharmacodynamics (PD) and Preliminary Activity in Acute Leukemia of Ory-1001, a First-in-Class Inhibitor of Lysine-Specific Histone Demethylase 1A (LSD1/KDM1A): Initial Results from a First-in-Human Phase 1 Study

BLOOD

AMER SOC HEMATOLOGY

1. Celgene
2. Sunesis
3. Amgen
4. Novartis
5. Chugai